Robert Bosch Venture Capital has returned for a $13.5m round that came four years after the diagnostic technology developer's series B.
Germany-based molecular diagnostics technology developer GNA Biosolutions has completed a $13.5m series C round backed by industrial product manufacturer Robert Bosch’s corporate venturing arm, Robert Bosch Venture Capital (RBVC).
The round included GreyBird Ventures, Occident, Wachstumsfonds Bayern, SHS Gesellschaft für Beteiligungsmanagement, UVC Partners, Mey Capital Matrix, KfW and Btov Partners, while Greybird partner Tom Miller has been appointed chairman of GNA.
GNA provides technology used by clinical laboratories to detect infectious diseases. Its platform provides molecular diagnostic by leveraging Pulse Controlled Amplification technology, which…
